An MR contrast agent with whole-body appeal
On 22 September 2016, 19 years after its initial approval on 22 July 1997 for dedicated MRI of the liver, MultiHance from Bracco Imaging received approval within Europe for use in MRI...
Relaxivity matters in contrast-enhanced MRI
Alain Bonafé from Gui de Chauliac Hospital, Montpellier, France, outlines the results of the BENEFIT study, which found confirmatory evidence that relaxivity matters in the use...
Improved contrast enhancement in MRI
MultiHance is a contrast agent for MRI, delivering greater contrast enhancement than other approved agents at equivalent doses. It has demonstrated excellent diagnostic performance...
GBCAs for enhanced MRI of brain tumours
Miles Kirchin from the division of global medical and regulatory affairs at Bracco Imaging reports the results of a study into the relative efficacy of non-ionic...
Compare and contrast
Choosing the right contrast agent can be the difference between spotting and missing malignant breast cancer growths. Success under the toughest possible scrutiny has proved that...
The contrast agent of choice
Bracco Imaging is one of the world’s leading companies in the development of new imaging solutions. MultiHance, its contrast agent for use in diagnostic magnetic resonance...
